Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731167 | 0.82 | RPA1 (0.74) | RPA1NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL1180189 | 0.81 | RPA1 (0.42) | RPA1NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL1180133 | 0.81 | RPA1 (0.42) | RPA1ALDH1A1HPGDKDM4ECNR2 | |
| SCHEMBL4631024 | 0.80 | CNR2 (0.43) | RPA1NR4A1NR4A2NR4A3CNR2 | |
| SCHEMBL1660340 | 0.75 | RPA1 (0.65) | RPA1NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL4896592 | 0.75 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ECNR2SIRT5 | |
| SCHEMBL3416828 | 0.75 | ALDH1A1 (0.64) | RPA1NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL4184540 | 0.75 | GAA (0.47) | RPA1ALDH1A1HPGDKDM4EMEN1 | |
| SCHEMBL30111996 | 0.75 | RPA1 (0.78) | RPA1NR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL19556314 | 0.75 | RPA1 (0.78) | RPA1NR4A1NR4A2NR4A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1981878-B1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007090493-A1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090493-A1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1765788-A2 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005123688-A2 | 3-AMINOINDAZOLES | MERCK PATENT GMBH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | RPA1 3408/4885NR4A1 1134/4885NR4A2 1406/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | RPA1 4220/4885NR4A1 2457/4885NR4A2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.